Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Alexander Wilkinson, Eric Lattmann, Carla B. Roces, Gabriel K. Pedersen, Dennis Christensen, Yvonne Perrie

Journal title: Journal of Controlled Release

Journal number: 291

Journal publisher: Elsevier BV

Published year: 2018

Published pages: 1-10

DOI identifier: 10.1016/j.jconrel.2018.10.002

ISSN: 0168-3659